• KOLs Community
    • Chronic
    • Chronic Hepatitis
    • Heiner H Wedemeyer
    • Heiner H Wedemeyer

      Heiner H Wedemeyer

      Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany | Department of Gastroenterology, ...



      KOL Resume for Heiner H Wedemeyer


      Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany

      Hannover Medical School (MHH)


      Department of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany;, (L.E.B.-M.);, (J.D.);, (F.N.);, (L.S.);, (M.L.);, (M.P.M.);, (H.W.);, (E.J.)

      Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

      German Centre for Infection Research (Deutsches Zentrum für Infektionsforschung DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany

      Hannover Medical School: Medizinische Hochschule Hannover



      Heiner H Wedemeyer: Influence Statistics

      Sample of concepts for which Heiner H Wedemeyer is among the top experts in the world.
      Concept World rank
      nonost ost #1
      hepatitis 75 #1
      disease burden hcv #1
      hdvrna hbsag #1
      humans hepatitis delta #1
      telaprevir access #1
      hbv treatment rate #1
      pegifnα 95 #1
      severe form #1
      aih pwm #1
      hdv genotype 1 #1
      svr proportion #1
      neuronal‐derived cells #1
      dhcr nonost patients #1
      verhinderung #1
      liver cirrhosis infection #1
      2000 iu risk #1
      hcv elimination daa #1
      hev replication tnfα #1
      hbcrag cell response #1
      immunotherapy tg4040 #1
      sims machine learning #1
      chronic hepatitis delta #1
      ost structural barriers #1
      hev rna brazil #1
      hbeag‐negative chb #1
      hbv polymerase inhibitors #1
      telaprevir access program #1
      hevinfections #1
      analogs therapy germany #1
      virological failure treatment #1
      chronic hcv glecaprevirpibrentasvir #1
      liver hev #1
      extra‐hepatic replication #1
      simplified 95 95 #1
      nonost patients alcohol #1
      12 weeks tvr #1
      patients low hbsag #1
      ost proportion #1
      graft hepatitis #1
      chronic hcv germany #1
      hev rna replication #1
      tnfα hev infection #1
      controls hbv patients #1
      hcv patients eaa #1
      commercial pork livers #1
      dynamo 1 #1
      hev infection lod #1
      entecavir vr #1
      ost nonost ndu #1


      Prominent publications by Heiner H Wedemeyer

      KOL-Index: 24011

      BACKGROUND: Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in the most severe form of viral hepatitis. There is no currently approved treatment. We investigated the safety and efficacy of 48 weeks of treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon alfa-2a alone, and adefovir dipivoxil alone.

      METHODS: We conducted a randomized trial in which 31 patients with HDV infection received treatment with 180 μg of peginterferon alfa-2a ...

      Known for Hdv Rna | Adefovir Peginterferon | Hepatitis Delta | 48 Weeks | Polyethylene Glycols
      KOL-Index: 20701

      BACKGROUND: Direct-acting antivirals for chronic hepatitis C (HCV) infection have reduced the need for on-treatment HCV RNA monitoring. We assessed the accuracy and cost implications of using HCV core antigen testing to replace HCV RNA testing for confirmation of diagnosis, on-treatment monitoring, and determination of sustained virological response (SVR).

      METHODS: In a retrospective screening cohort study, de-identified residual serum from unselected samples were obtained from ...

      Known for Hcv Rna | Core Antigen | Acting Antivirals | 12 Weeks | Treatment Monitoring
      KOL-Index: 17133

      CONTEXT: Chronic hepatitis C virus (HCV) infection outcomes include liver failure, hepatocellular carcinoma (HCC), and liver-related death.

      OBJECTIVE: To assess the association between sustained virological response (SVR) and all-cause mortality in patients with chronic HCV infection and advanced hepatic fibrosis.

      DESIGN, SETTING, AND PATIENTS: An international, multicenter, long-term follow-up study from 5 large tertiary care hospitals in Europe and Canada of 530 patients with chronic ...

      Known for Advanced Hepatic Fibrosis | Virological Response | 95 Svr | Chronic Hepatitis | Liver Failure
      KOL-Index: 16519

      BACKGROUND & AIMS: Hepatitis delta virus (HDV) infection is the most severe form of viral hepatitis. Although HDV-associated liver disease is considered immune-mediated, adaptive immune responses against HDV are weak. Thus, the role of several other cell-mediated mechanisms such as those driven by mucosa-associated invariant T (MAIT) cells, a group of innate-like T cells highly enriched in the human liver, has not been extensively studied in clinical HDV infection.

      METHODS: MAIT cells ...

      Known for Mait Cells | Chronic Hepatitis | Delta Virus | Hdv Infection | Severe Form
      KOL-Index: 16415

      BACKGROUND: Hepatitis B surface antigen (HBsAg) clearance during chronic hepatitis B (CHB) infection is associated with improved long-term clinical outcome, so is considered an important therapeutic goal in CHB. Studies have shown that serum HBsAg quantification during, and at end of, treatment may predict long-term HBsAg loss.

      OBJECTIVES: Performance comparison of the qualitative Elecsys HBsAg II assay using a quantitative research protocol and an established quantitative HBsAg ...

      Known for Elecsys Hbsag | Architect Assay | Antigens Hepatitis | Hbv Genotype | Surface Antigen
      KOL-Index: 16225

      BACKGROUND: The elimination of hepatitis B virus surface antigen (HBsAg) is the final goal of hepatitis B treatment, but is rarely achieved. As quantitative assays for HBsAg recently became available, we have investigated whether quantitative HBsAg measurements can substitute for hepatitis B virus (HBV) DNA quantification in treatment monitoring.

      METHODS: Within this study, 23 liver transplant patients and 18 heart transplant recipients were retrospectively analysed. Patients had been ...

      Known for Hbv Dna | Surface Antigen | Hbsag Hbeag | Hepatitis Virus | 100 Iu
      KOL-Index: 16168

      BACKGROUND & AIMS: Treatment with nucleos(t)ide analogues (NA) leads to hepatitis B virus (HBV) DNA suppression in most patients with chronic hepatitis B (CHB), but HBV surface antigen (HBsAg) loss rates are low. Upon NA discontinuation, HBV DNA can return rapidly with ensuing alanine aminotransferase flares and induction of cytokines. Several studies reported higher HBsAg loss rates after stopping therapy, but at present it is unclear if cell-mediated immune responses are altered after ...

      Known for Cell Responses | Chronic Hepatitis | Discontinuation Therapy | Hbsag Loss | Patients Chb
      KOL-Index: 16097

      BACKGROUND & AIMS: The European Association for the Study of the Liver (EASL) guidelines recommend HCV RNA measurements at specific time points during sofosbuvir(SOF)-therapy. However, it remains unclear, how these results should be interpreted. We aimed to analyze whether on-treatment HCV RNA levels predict relapse comparing the CobasAmpliPrep/CobasTaqMan v2.0 (CAP/CTM) and Abbott RealTime HCV (ART) assays.

      METHODS: Samples were collected from 298 patients (HCV genotypes; GT1-5) at ...

      Known for Hcv Rna | Art Patients | Cap Ctm | Antiviral Therapy | Sofosbuvir Based
      KOL-Index: 14981

      BACKGROUND & AIMS: The quantifiable level of HBsAg has been suggested as a predictor of treatment response in chronic hepatitis B. However, there is limited information on HBsAg levels considering the dynamic natural course of HBV-infection. This study aimed to determine HBsAg levels in the different phases of HBV-infection in European HBsAg-positive patients.

      METHODS: 226 HBV-monoinfected patients, not undergoing antiviral therapy, were analyzed in a cross-sectional study. Patients were ...

      Known for Hbsag Hbv | Acute Hepatitis | Antiviral Therapy | Studies Dna | Genotype Patients
      KOL-Index: 14518

      BACKGROUND: Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnucleoside polymerase inhibitor dasabuvir (ABT-333), and ribavirin in an open-label phase 3 trial involving previously untreated and previously treated adults ...

      Known for Sustained Virologic Response | 12 Weeks Treatment | Abt450 Ombitasvir | Patients Cirrhosis | Dasabuvir Ribavirin
      KOL-Index: 14312

      BACKGROUND AND AIMS: Novel, potent, and well-tolerated hepatitis C virus (HCV) drugs are needed. BILN 2061 is a potent and specific inhibitor of HCV serine protease in vitro. Preclinical toxicology data and studies in healthy volunteers supported the administration of BILN 2061 to patients with HCV infection.

      METHODS: The antiviral efficacy, pharmacokinetics, and tolerability of 25, 200, and 500 mg BILN 2061 twice daily given as monotherapy for 2 days in 31 patients infected with chronic ...

      Known for Biln 2061 | Antiviral Efficacy | Genotype 1 | Protease Inhibitor | Compensated Cirrhosis
      KOL-Index: 14293

      Different viral dominance patterns have been documented in coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) based on HBV DNA and HCV RNA quantification. In most cases, HCV is dominant and suppresses HBV replication. In vitro studies revealed that there is most probably no direct interference between HBV and HCV replication. We hypothesized that indirect mechanisms mediated by host immune responses might be responsible for the different dominance patterns. In this ...

      Known for Hbv Hcv | Hepatitis Virus | Coinfected Patients | Surface Antigen | Protein 10
      KOL-Index: 14023

      BACKGROUND: Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir (ETV)-treated patients. We aimed to study risk factors and performance of risk scores during ETV treatment in an ethnically diverse Western population.

      METHODS: We studied all HBV monoinfected patients treated with ETV from 11 European referral centres within the VIRGIL Network.

      RESULTS: A total of 744 patients were included; 42% Caucasian, 29% Asian, 19% other, 10% unknown. At baseline, 164 ...

      Known for Risk Scores | Hepatocellular Carcinoma | Entecavir Treatment | Chronic Hepatitis | Hcc Baseline
      KOL-Index: 13800

      Recent studies suggest that diabetes mellitus increases the risk of developing hepatocellular carcinoma (HCC). The aim of this study is to quantify the risk of HCC among patients with both diabetes mellitus and hepatitis C in a large cohort of patients with chronic hepatitis C and advanced fibrosis. We included 541 patients of whom 85 (16%) had diabetes mellitus. The median age at inclusion was 50 years. The prevalence of diabetes mellitus was 10.5% for patients with Ishak fibrosis score ...

      Known for Diabetes Mellitus | Hcc Patients | Hepatocellular Carcinoma | Hepatitis Cirrhosis | Advanced Fibrosis

      Key People For Chronic Hepatitis

      Top KOLs in the world
      Patrick Marcellin
      chronic hepatitis adefovir dipivoxil hcv genotype
      Michael Peter Manns
      chronic hepatitis liver transplantation hepatocellular carcinoma
      Anna Shuk‐Fong Lok
      chronic hepatitis hepatocellular carcinoma united states
      Stefan S Zeuzem
      chronic hepatitis hcv genotype liver fibrosis
      Jay H Hoofnagle¶¶
      chronic hepatitis liver injury united states
      Zachary D Goodman
      chronic hepatitis liver fibrosis hepatocellular carcinoma

      Heiner H Wedemeyer:Expert Impact

      Concepts for whichHeiner H Wedemeyerhas direct influence:Chronic hepatitis,  Hepatitis virus,  Hepatitis delta,  Liver cirrhosis,  Hcv rna,  Acute hepatitis,  Liver transplantation,  Hdv rna.

      Heiner H Wedemeyer:KOL impact

      Concepts related to the work of other authors for whichfor which Heiner H Wedemeyer has influence:Chronic hepatitis,  Hepatocellular carcinoma,  Hcv infection,  Liver disease,  Nk cells,  Antiviral therapy,  Hbv dna.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany | Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany;, wed

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.